Evidence map›Paper›PMID 31533739›Full record

ArticleMalaria journal2019

Eave ribbons treated with transfluthrin can protect both users and non-users against malaria vectors.

Emmanuel P Mwanga, Arnold S Mmbando, Paul C Mrosso, Caleb Stica, Salum A Mapua, Marceline F Finda, Khamis Kifungo, Andrew Kafwenji, April C Monroe, Sheila B Ogoma and 2 more

Abstract read
In one paragraph

Article in Malaria journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Emmanuel P MwangaEnvironmental Health and Ecological Sciences Department, Ifakara Health Institute, Morogoro, Tanzania. emwanga@ihi.or.tz.ORCID http://orcid.org/0000-0003-1799-3830
Arnold S MmbandoEnvironmental Health and Ecological Sciences Department, Ifakara Health Institute, Morogoro, Tanzania.
Paul C MrossoEnvironmental Health and Ecological Sciences Department, Ifakara Health Institute, Morogoro, Tanzania.
Caleb SticaEnvironmental Health and Ecological Sciences Department, Ifakara Health Institute, Morogoro, Tanzania.
Salum A MapuaEnvironmental Health and Ecological Sciences Department, Ifakara Health Institute, Morogoro, Tanzania.
Marceline F FindaEnvironmental Health and Ecological Sciences Department, Ifakara Health Institute, Morogoro, Tanzania.
Khamis KifungoEnvironmental Health and Ecological Sciences Department, Ifakara Health Institute, Morogoro, Tanzania.
Andrew KafwenjiEnvironmental Health and Ecological Sciences Department, Ifakara Health Institute, Morogoro, Tanzania.
April C MonroeEnvironmental Health and Ecological Sciences Department, Ifakara Health Institute, Morogoro, Tanzania.
Sheila B OgomaEnvironmental Health and Ecological Sciences Department, Ifakara Health Institute, Morogoro, Tanzania.
Halfan S NgowoEnvironmental Health and Ecological Sciences Department, Ifakara Health Institute, Morogoro, Tanzania.
Fredros O OkumuEnvironmental Health and Ecological Sciences Department, Ifakara Health Institute, Morogoro, Tanzania.

Funding

Howard Hughes Medical Institute OPP1099295Wellcome TrustWellcome Trust WT102350/Z/13/Z
6 · The paper itself

Abstract

backgroundEave ribbons treated with spatial repellents effectively prevent human exposure to outdoor-biting and indoor-biting malaria mosquitoes, and could constitute a scalable and low-cost supplement to current interventions, such as insecticide-treated nets (ITNs). This study measured protection afforded by transfluthrin-treated eave ribbons to users (personal and communal protection) and non-users (only communal protection), and whether introducing mosquito traps as additional intervention influenced these benefits.

methodsFive experimental huts were constructed inside a 110 m long, screened tunnel, in which 1000 Anopheles arabiensis were released nightly. Eave ribbons treated with 0.25 g/m

resultsTransfluthrin-treated eave ribbons provided 83% and 62% protection indoors and outdoors respectively to users, plus 57% and 48% protection indoors and outdoors to the non-user. Protection for users remained constant, but protection for non-users increased with eave ribbons coverage, peaking once 80% of huts were fitted. Mortality of mosquitoes caged inside huts with eave ribbons was 100%. The UV-LED traps increased indoor exposure to users and non-users, but marginally reduced outdoor-biting. Combining the traps and eave ribbons did not improve user protection relative to eave ribbons alone.

conclusionTransfluthrin-treated eave ribbons protect both users and non-users against malaria mosquitoes indoors and outdoors. The mosquito-killing property of transfluthrin can magnify the communal benefits by limiting unwanted diversion to non-users, but should be validated in field trials against pyrethroid-resistant vectors. Benefits of the UV-LED traps as an intervention alone or alongside eave ribbons were however undetectable in this study. These findings extend the evidence that transfluthrin-treated eave ribbons could complement ITNs.

Indexed as

AnophelesCyclopropanesFluorobenzenesInsect RepellentsMosquito ControlMosquito VectorsAdultAnimalsHumansInsect Bites and StingsMalariaMaleTanzaniaYoung AdultCyclopropanesFluorobenzenesInsect RepellentstransfluthrinAnopheles arabiensisEave ribbonsIfakara Health InstituteMalariaMosquito trapsOutdoor bitingPush–pullSpatial repellentsTanzaniaTransfluthrin

Identifiers

PMID31533739
PMCPMC6751741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.